Loading…
Based on limited metadata, the FDA issued a warning letter to Yibin Lihao Bio-technical Co., Ltd., a drug manufacturer, on February 13, 2020. Without access to the full letter text or specific subject line details, the exact nature of the violations cannot be determined from the available information. The letter falls under FDA's drug product regulatory authority, though the specific issuing office is not identified in the metadata provided. Additional documentation would be needed to identify the particular compliance issues cited.